Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319165 | 0.81 | TSHR (0.37) | FDPS | |
| SCHEMBL5932057 | 0.79 | FDPS (0.48) | FDPS | |
| SCHEMBL3900432 | 0.77 | — | — | |
| SCHEMBL1741714 | 0.74 | — | — | |
| SCHEMBL11582857 | 0.74 | FDPS (0.38) | FDPSCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1339269 | 0.72 | — | — | |
| Bromide SCHEMBL2225990 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL1897139 | 0.69 | — | — | |
| SCHEMBL14136210 | 0.69 | FDPS (0.35) | FDPSCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL827253 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087093-B1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2021-11-10 | — | — | EP | claimed |
| US-20050281855-A1 | Process for preparing a cross-linked carboxyl polysaccharide and the cross-linked carboxyl polysaccharide | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2005-12-22 | — | — | US | claimed |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-08-22 | — | — | US | disclosed |
| EP-4346811-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022256419-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-3122344-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210008055-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2021-01-14 | — | — | US | disclosed |
| EP-3122345-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3122346-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190275024-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2012064911-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2408304-A1 | CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010107605-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2006089311-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20050281855-A1 | Process for preparing a cross-linked carboxyl polysaccharide and the cross-linked carboxyl polysaccharide | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | FDPS 1431/4885CYP1A2 2002/4885CYP3A4 3910/4885 |
| US-20210008055-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | FDPS 1431/4885CYP1A2 2002/4885CYP3A4 3910/4885 |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | FDPS 1431/4885CYP1A2 2002/4885CYP3A4 3910/4885 |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | FDPS 2891/4885CYP1A2 1048/4885CYP3A4 2986/4885 |
| US-20050281855-A1 | Process for preparing a cross-linked carboxyl polysaccharide and the cross-linked carboxyl polysaccharide | CSGALNACT1, GNE, ALG1 | FDPS 3810/4885CYP1A2 4089/4885CYP3A4 2215/4885 |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | NGFR, NTRK2, NGF | FDPS 1671/4885CYP1A2 2660/4885CYP3A4 4102/4885 |
| US-20190275024-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | FDPS 1431/4885CYP1A2 2002/4885CYP3A4 3910/4885 |
| US-20240279201-A1 | DUAL WNT SIGNALING PATHWAY INHIBITORS AND AMPK ACTIVATORS FOR TREATMENTS OF DISEASE | PRKAB2, PRKAB1, PRKAG2 | FDPS 3321/4885CYP1A2 1760/4885CYP3A4 3818/4885 |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | FDPS 1431/4885CYP1A2 2002/4885CYP3A4 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.